Polaryx Therapeutics (PLYX) Share-based Compensation (2024 - 2026)

Polaryx Therapeutics (PLYX) has reported Share-based Compensation for 3 consecutive years, with $7.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 6937.04% year-over-year to $7.6 million in Q2 2026; TTM through Jun 2026 was $7.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $7.6 million, up 184.58% from the prior year.
• Share-based Compensation was $7.6 million for Q2 2026 at Polaryx Therapeutics, roughly flat from $7.6 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $7.6 million in Q1 2026 and troughed at $108000.0 in Q2 2025.
• A 3-year average of $4.4 million and a median of $4.3 million in 2025 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation jumped 56.75% in 2025 and surged 6937.04% in 2026, its largest moves.
• Over 3 years, Share-based Compensation stood at $2.7 million in 2024, then jumped by 56.75% to $4.2 million in 2025, then soared by 81.55% to $7.6 million in 2026.
• The last three Share-based Compensation figures came in at $7.6 million (Q2 2026), $7.6 million (Q1 2026), and $4.2 million (Q4 2025), per Business Quant data.